Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

Stock Information for Eagle Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer
Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Aldeyra, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.